Intermediate-conductance Ca2+-activated K+ channel, KCa3.1, as a novel therapeutic target for benign prostatic hyperplasia

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 2, 2011, Pages 528-536

  Ohya, Susumu ^a   Niwa, Satomi ^a   Kojima, Yoshiyuki ^b   Sasaki, Shoichi ^b   Sakuragi, Motomu ^c   Kohri, Kenjiro ^b   Imaizumi, Yuji ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; CYCLINE; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PROTEIN C JUN; REPRESSOR ELEMENT 1 SILENCING TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CALCIUM ACTIVATED POTASSIUM CHANNEL; KCNN4 PROTEIN, RAT; PYRAZOLE DERIVATIVE; TRAM 34;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL; TRANSCRIPTION REGULATION; UPREGULATION; UROGENITAL SINUS; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; HUMANS; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MALE; MIDDLE AGED; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; PROSTATIC HYPERPLASIA; PYRAZOLES; RATS; YOUNG ADULT;

EID: 79960477566     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.182782     Document Type: Article

References (39)

1. Albert AP, Saleh SN, Peppiatt-Wildman CM, and Large WA (2007) Multiple activation mechanisms of store-operated TRPC channels in smooth muscle cells. J Physiol 583:25-36. (Pubitemid 47244242)
2. Andersson KE and Gratzke C (2007) Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 4:368-378.
3. Bartsch G, Müller HR, Oberholzer M, and Rohr HP (1979) Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 122:487-491. (Pubitemid 10245530)
4. Berry SJ, Coffey DS, Walsh PC, and Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474-479. (Pubitemid 14026148)
5. Chang S, Gomes CM, Hypolite JA, Marx J, Alanzi J, Zderic SA, Malkowicz B, Wein AJ, and Chacko S (2010) Detrusor overactivity is associated with downregulation of large-conductance calcium- and voltage-activated potassium channel protein. Am J Physiol Renal Physiol 298:F1416-F1423.
6. Cheong A, Bingham AJ, Li J, Kumar B, Sukumar P, Munsch C, Buckley NJ, Neylon CB, Porter KE, Beech DJ, et al.(2005) Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. Mol Cell 20:45-52. (Pubitemid 41396561)
7. Djavan B (2003) Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life. Urology 62:6-14.
8. Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, Gutman GA, Cahalan MD, and Chandy KG (2000) Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem 275:37137-37149. (Pubitemid 32002132)
9. Gravas S and Oelke M (2010) Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 28:9-15.
10. Grgic I, Kiss E, Kaistha BP, Busch C, Kloss M, Sautter J, Müller A, Kaistha A, Schmidt C, Raman G, et al. (2009) Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci USA 106:14518-14523.
11. Guibert C, Ducret T, and Savineau JP (2008) Voltage-independent calcium influx in smooth muscle. Prog Biophys Mol Biol 98:10-23.
12. House SJ, Potier M, Bisaillon J, Singer HA, and Trebak M (2008) The non-excitable smooth muscle: calcium signaling and phenotypic switching during vascular disease. Pflugers Arch 456:769-785.
13. Inoue R, Jensen LJ, Shi J, Morita H, Nishida M, Honda A, and Ito Y (2006) Transient receptor potential channels in cardiovascular function and disease. Circ Res 99:119-131. (Pubitemid 44297035)
14. Ishigooka M, Hayami S, Hashimoto T, Suzuki Y, Katoh T, and Nakada T (1996) Relative and total volume of histological components in benign prostatic hyperplasia: relationships between histological components and clinical findings. Prostate 29:77-82. (Pubitemid 26287106)
15. Ishii TM, Silvia C, Hirschberg B, Bond CT, Adelman JP, and Maylie J (1997) A human intermediate conductance calcium-activated potassium channel. Proc Natl Acad Sci USA 94:11651-11656. (Pubitemid 127650718)
16. Kajanne R, Miettinen P, Tenhunen M, and Leppä S (2009) Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells. Int J Oncol 35:1175-1182.
17. Kojima Y, Sasaki S, Hayashi Y, Tsujimoto G, and Kohri K (2009a) Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine. Nat Clin Pract Urol 6:44-53.
18. Kojima Y, Sasaki S, Oda N, Koshimizu TA, Hayashi Y, Kiniwa M, Tsujimoto G, and Kohri K (2009b) Prostate growth inhibition by subtype-selective alpha(1)- adrenoceptor antagonist naftopidil in benign prostatic hyperplasia. Prostate 69:1521-1528.
19. Köhler R, Wulff H, Eichler I, Kneifel M, Neumann D, Knorr A, Grgic I, Kämpfe D, Si H, Wibawa J, et al. (2003) Blockade of the intermediate-conductance calciumactivated potassium channel as a new therapeutic strategy for restenosis. Circulation 108:1119-1125. (Pubitemid 37071524)
20. Li W, Wu CL, Febbo PG, and Olumi AF (2007) Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol 171:1189-1198. (Pubitemid 47582893)
21. Liang CZ, Guo QK, Hao ZY, Yang S, Wang DB, Wu LX, Liu C, Wang KX, and Zhang XJ (2006) K channel expression in prostate epithelium and its implications in men with chronic prostatitis. BJU Int 97:190-192.
22. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, et al. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387-2398. (Pubitemid 37542987)
23. Mori F, Oda N, Sakuragi M, Sakakibara F, Kiniwa M, and Miyoshi K (2009) New histopathological experimental model for benign prostatic hyperplasia: stromal hyperplasia in rats. J Urol 181:890-898.
24. + channel in Jurkat T-lymphocyte. J Pharmacol Sci 104:94-98.
25. Neylon CB, Lang RJ, Fu Y, Bobik A, and Reinhart PH (1999) Molecular cloning and characterization of the intermediate-conductance Ca(2+)-activated K(+) channel in vascular smooth muscle: relationship between K(Ca) channel diversity and smooth muscle cell function. Circ Res 85:e33-e43.
26. Ohya S, Kimura K, Niwa S, Ohno A, Kojima Y, Sasaki S, Kohri K, and Imaizumi Y (2009) Malignancy grade-dependent expression of K+-channel subtypes in human prostate cancer. J Pharmacol Sci 109:148-151.
27. Ohya S, Kimura S, Kitsukawa M, Muraki K, Watanabe M, and Imaizumi Y (2000) SK4 encodes intermediate conductance Ca2+-activated K+ channels in mouse urinary bladder smooth muscle cells. Jpn J Pharmacol 84:97-100.
28. Ohya S, Kuwata Y, Sakamoto K, Muraki K, and Imaizumi Y (2005) Cardioprotective effects of estradiol include the activation of large-conductance Ca(2+)-activated K(+) channels in cardiac mitochondria. Am J Physiol Heart Circ Physiol 289: H1635-H1642. (Pubitemid 41369007)
29. Park S, Kim JA, Joo KY, Choi S, Choi EN, Shin JA, Han KH, Jung SC, and Suh SH (2011) Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease. Cardiovasc Res 89:290-299.
30. Pollard M, Luckert PH, and Snyder D (1989) Prevention and treatment of experimental prostate cancer in Lobund-Wistar rats. I. Effects of estradiol, dihydrotestosterone, and castration. Prostate 15:95-103. (Pubitemid 19262138)
31. Ricote M, Royuela M, García-Tuñón I, Bethencourt FR, Paniagua R, and Fraile B (2003) Pro-apoptotic tumor necrosis factor-alpha transduction pathway in normal prostate, benign prostatic hyperplasia and prostatic carcinoma. J Urol 170:787-790. (Pubitemid 36999556)
32. Shapiro E, Becich MJ, Hartanto V, and Lepor H (1992) The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 147:1293-1297.
33. Si H, Heyken WT, Wölfle SE, Tysiac M, Schubert R, Grgic I, Vilianovich L, Giebing G, Maier T, Gross V, et al. (2006) Impaired endothelium-derived hyperpolarizing factor-mediated dilations and increased blood pressure in mice deficient of the intermediate-conductance Ca2+-activated K+ channel. Circ Res 99:537-544. (Pubitemid 44337826)
34. Stocker M (2004) Ca(2+)-activated K+ channels: molecular determinants and function of the SK family. Nat Rev Neurosci 5:758-770.
35. Tharp DL, Wamhoff BR, Turk JR, and Bowles DK (2006) Upregulation of intermediate-conductance Ca2+-activated K+ channel (IKCa1) mediates phenotypic modulation of coronary smooth muscle. Am J Physiol Heart Circ Physiol 291:H2493-H2503.
36. Tharp DL, Wamhoff BR, Wulff H, Raman G, Cheong A, and Bowles DK (2008) Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb Vasc Biol 28:1084-1089.
37. Wang ZH, Shen B, Yao HL, Jia YC, Ren J, Feng YJ, and Wang YZ (2007) Blockage of intermediate-conductance Ca(2+)-activated K(+) channels inhibits progression of human endometrial cancer. Oncogene 26:5107-5114. (Pubitemid 47206942)
38. Wisdom R (1999) AP-1: one switch for many signals. Exp Cell Res 253:180-185.
39. Wulff H, Kolski-Andreaco A, Sankaranarayanan A, Sabatier JM, and Shakkottai V (2007) Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem 14:1437-1457. (Pubitemid 46902225)